Trial
NCT03274258
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Kidney Medullary Carcinoma
Intervention
Ipilimumab
Why stopped
The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-03